Ros S, Agüera L, de la Gándara J, Rojo J E, de Pedro J M
Hospital del Mar, Barcelona, Spain.
Acta Psychiatr Scand Suppl. 2005(428):14-24, 36. doi: 10.1111/j.1600-0447.2005.00676.x.
To review the pharmacological basis of antidepressant potentiation in combination therapy and the clinical evidence for its efficacy.
Literature searches were undertaken and the results reviewed.
Treatment-resistant depression is common (15-30%). Various strategies exist for dealing with resistant depression, including pharmacological potentiation, i.e. adding a treatment that itself does not have antidepressant actions but that enhances the efficacy of the original treatment. Lithium, triiodothyronine (T3) and buspirone are the best studied potentiating drugs, although other options include pindolol, dopaminergic agents, second-generation antipsychotics, psychostimulants, hormones and anticonvulsants.
Several pharmacological potentiation strategies exist. Whilst good evidence exists for lithium combined with antidepressants, although good results have also been reported with augmentation strategies involving T3 or buspirone.
回顾联合治疗中抗抑郁增效的药理学基础及其疗效的临床证据。
进行文献检索并对结果进行综述。
难治性抑郁症很常见（15%-30%）。处理难治性抑郁症有多种策略，包括药理学增效，即添加一种本身没有抗抑郁作用但能增强原治疗疗效的治疗方法。锂盐、三碘甲状腺原氨酸（T3）和丁螺环酮是研究最多的增效药物，不过其他选择还包括吲哚洛尔、多巴胺能药物、第二代抗精神病药物、精神兴奋剂、激素和抗惊厥药。
存在多种药理学增效策略。虽然有充分证据支持锂盐与抗抑郁药联合使用，但涉及T3或丁螺环酮的增效策略也报告了良好结果。
